Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds BTIG Downgrades Magenta Therapeutics to Neutral

BTIG Downgrades Magenta Therapeutics to Neutral

BTIG analyst Yun Zhong downgrades Magenta Therapeutics (NASDAQ:MGTA) from Buy to Neutral.

byBenzinga Newsdesk

January 26, 2023

1 minute read

BTIG analyst Yun Zhong downgrades Magenta Therapeutics (NASDAQ:MGTA) from Buy to Neutral.

This Highly Differentiated Cybersecurity Stock Gives Lot Of Confidence To Analysts Amid Improving Demand Trends

By Anusuya Lahiri

September 21, 2:51 PM

Analysts attended CrowdStrike Holdings, Inc's (NASDAQ: CRWD) annual user conference called Fal.Con, where management also hosted an investor briefing

CRWD

Analyst Ratings

Forecasting The Future: 4 Analyst Projections For Xometry

By Benzinga Insights

April 23, 11:01 AM

Across the recent three months, 4 analysts have shared their insights on Xometry (NASDAQ:XMTR), expressing a variety of…

XMTR

EXCLUSIVE: Expert Advice On How To Become Compliant Psychedelics Cultivator And Manufacturer

By Lara Goldstein

October 27, 11:41 AM

What can businesses and clients expect from psychedelic-assisted therapies (PAT)? What are state regulations looking like from a for-profit perspective and what does it take to provide safe, effective and compliant treatments?

AMZN

Analyst Ratings

Expert Ratings for Warner Music Gr

By Benzinga Insights

November 15, 4:00 PM

Over the past 3 months, 9 analysts have published their opinion on Warner Music Gr (NASDAQ:WMG) stock. These…

WMG

BTIG Downgrades Magenta Therapeutics to Neutral

Related Posts

This Highly Differentiated Cybersecurity Stock Gives Lot Of Confidence To Analysts Amid Improving Demand Trends

Forecasting The Future: 4 Analyst Projections For Xometry

EXCLUSIVE: Expert Advice On How To Become Compliant Psychedelics Cultivator And Manufacturer

Expert Ratings for Warner Music Gr